Immunohistochemistry

Malignant Mesothelioma: Advances in Pathogenesis, Diagnosis, and Translational Therapies

Volumn , Issue , 2005, Pages 490-507

  Pier Giacomo, Betta ^a  

^a C Arrigo Children's Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33745721075     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/0-387-28274-2_32     Document Type: Chapter

References (35)

1. Battifora H, McCaughey W T E. Tumours of the Serosal Membranes. Atlas of Tumour Pathology, Third Series, Fascicle 15. Washington, DC: Armed Forces Institute of Pathology, 1994.
2. Cagle P, Corson J, Gibbs AR, et al. The separation of benign and malignant mesothelial proliferations. Am J Surg Pathol 2000;24:1183-1200.
3. Singh G, Whiteside TL, Dekker A. Immunodiagnosis of mesothelioma: use of anti-mesothelial cell serum in an indirect immunofluorescence assay. Cancer 1979;43:2288-2296.
4. Moran CA, Wick MR, Suster S. The role of immunohistochemistry in the diagnosis of malignant mesothelioma. Semin Diagn Pathol 2000;17:178-183.
5. King JE, Hasleton PS. Immunohistochemistry and the diagnosis of malignant mesothelioma. Histopathology 2001;38:471-476.
6. Ordóñez NG. Immunohistochemical diagnosis of epithelioid mesotheliomas: a critical review of old markers, new markers. Hum Pathol 2002;33:953-967.
7. Donna A, Betta PG. Mesodermomas: a new embryological approach to primary tumours of coelomic surfaces. Histopathology 1981;5:31-44.
8. Attanoos RL, Webb R, Dojcinov SD, Gibbs AR. Malignant epithelioid mesothelioma: anti-mesothelial marker expression correlates with histological pattern. Histopathology 2001;39:584-588.
9. Chu PG, Weiss LM. Keratin expression in human tissues and neoplasms. Histopathology 2002;40:403-439.
10. Betta PG, Andrion A, Donna A, et al. Malignant mesothelioma of the pleura. The reproducibility of the immunohistological diagnosis. Pathol Res Pract 1997;193:759-765.
11. Osborn M, Pelling N, Walker MM, et al. The value of "mesothelium- associated" antibodies in distinguishing between metastatic renal cell carcinomas and mesotheliomas. Histopathology 2002;41:301-307.
12. Abutaily AS, Addis BJ, Roche WR. Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies. J Clin Pathol 2002;55(9):662-668.
13. Gumurdulu D, Zeren EH, Cagle PT, et al. Specificity of MOC-31 and HBME-1 immunohistochemistry in the differential diagnosis of adenocarcinoma and malignant mesothelioma: a study on environmental malignant mesothelioma cases from Turkish villages. Pathol Oncol Res 2002;8:188-193.
14. Gonzalez-Lois C, Ballestin C, Sotelo MT, et al. Combined use of novel epithelial (MOC-31) and mesothelial (HBME-1) immunohistochemical markers for optimal first line diagnostic distinction between mesothelioma and metastatic carcinoma in pleura. Histopathology 2001;38:528-534.
15. Roberts F, Harper CM, Downie I, et al. Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies. Am J Clin Pathol 2001;116:253-262.
16. Han AC, Peralta-Soler A, Knudsen KA, et al. Differential expression of Ncadherin in pleural mesotheliomas and E-cadherin in lung adenocarcinomas in formalin-fixed, paraffin-embedded tissues. Hum Pathol 1997;28:641-645.
17. Oates J, Edwards C. HBME-1, MOC-31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma. Histopathology 2000;36:341-347.
18. Lau SK, Luthringer DJ, Eisen RN. Thyroid transcription factor-1: a review. Appl Immunohistochem Mol Morphol 2002;10:97-102.
19. Donna A, Betta PG, Chiodera P, et al. Newly marketed tissue markers for malignant mesothelioma: immunoreactivity of rabbit AMAD-2 antiserum compared with monoclonal antibody HBME-1 and a review of the literature on so-called antimesothelioma antibodies. Hum Pathol 1997;28:929-937.
20. Donna A, Betta PG, Ribotta M, et al. Mitogenic effects of a mesothelial cell growth factor: evidence for a potential autocrine regulation of normal and malignant mesothelial cell proliferation. Int J Exp Pathol 1992;73:193-202.
21. Miettinen M, Kovatich AJ. HBME-1. A monoclonal antibody useful in the differential diagnosis of mesothelioma, adenocarcinoma, and soft-tissue and bone tumours. Appl Immunohistochem 1995;3:115-122.
22. Doglioni C, Tos AP, Laurino L, et al. Calretinin: a novel immunocytochemical marker for mesothelioma. Am J Surg Pathol 1996;20:1037-1046.
23. Miettinen M, Limon J, Niezabitowski A, et al. Calretinin and other mesothelioma markers in synovial sarcoma: analysis of antigenic similarities and differences with malignant mesothelioma. Am J Surg Pathol 2001;25:610-617.
24. Attanoos RL, Galateau-Salle F, Gibbs AR, et al. Primary thymic epithelial tumours of the pleura mimicking malignant mesothelioma. Histopathology 2002;41:42-49.
25. Yu GH, Soma L, Hahn S, et al. Changing clinical course of patients with malignant mesothelioma: implications for FNA cytology and utility of immunocytochemical staining. Diagn Cytopathol 2001;24:322-327.
26. Moll R, Dhouailly D, Sun TT. Expression of keratin 5 as a distinctive feature of epithelial and biphasic mesotheliomas. An immunohistochemical study using monoclonal antibody AE14. Virchows Arch B Cell Pathol Incl Mol Pathol 1989;58:129-145.
27. Ordonez NG. Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and non-pulmonary adenocarcinoma. Am J Surg Pathol 2000;24:598-606.
28. Foster MR, Johnson JE, Olson SJ, et al. Immunohistochemical analysis of nuclear versus cytoplasmic staining of WT1 in malignant mesotheliomas and primary pulmonary adenocarcinomas. Arch Pathol Lab Med 2001;125:1316-1320.
29. Hecht JL, Lee BH, Pinkus JL, et al. The value of Wilms tumour susceptibility gene 1 in cytologic preparations as a marker for malignant mesothelioma. Cancer 2002;96:105-109.
30. Muller AM, Weichert A, Muller KM. E-cadherin, E-selectin and vascular cell adhesion molecule: immunohistochemical markers for differentiation between mesothelioma and metastatic pulmonary adenocarcinoma? Virchows Arch 2002;441:41-46.
31. Mayall FG, Goddard H, Gibbs AR. Intermediate filaments expression in mesotheliomas: leiomyoid mesotheliomas are not uncommon. Histopathology 1992;21:453-457.
32. Kung IT, Thallas V, Spencer EJ, et al. Expression of muscle actins in diffuse mesotheliomas. Hum Pathol 1995;26:567-570.
33. Hurlimann J. Desmin and neural marker expression in mesothelial cells and mesotheliomas. Hum Pathol 1994;25:753-757.
34. Attanoos RL, Dojcinov SD, Webb R, et al. Anti-mesothelial markers in sarcomatoid mesothelioma and other spindle-cell neoplasms. Histopathology 2000;37:224-231.
35. Kumaki F, Kawai T, Churg A, et al. Expression of telomerase reverse transcriptase (TERT) in malignant mesotheliomas. Am J Surg Pathol 2002;26:365-370.